

GIVEN BRUCE D
Form 4
February 12, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
GIVEN BRUCE D

2. Issuer Name and Ticker or Trading
Symbol
ARROWHEAD
PHARMACEUTICALS, INC.
[ARWR]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
X Officer (give title below) ____ Other (specify below)

Chief Operating Officer

225 S. LAKE AVENUE, SUITE
1050

(Street)

3. Date of Earliest Transaction
(Month/Day/Year)
02/08/2019

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

PASADENA, CA 91101

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/08/2019		M	11,667 A	\$ 2.62 859,523	D	
Common Stock	02/08/2019		S ⁽¹⁾	46,167 D	\$ 15.34 813,356	D	
Common Stock	02/11/2019		M	11,667 A	\$ 2.62 825,023	D	
Common Stock	02/11/2019		S ⁽¹⁾	97,167 D	\$ 15.66 727,856	D	

Edgar Filing: GIVEN BRUCE D - Form 4

(3)

Common Stock	02/11/2019	S ⁽¹⁾	57,000	D	\$ 16.48	670,856	D
Common Stock	02/12/2019	M	42,500	A	\$ 2.01	713,356	D
Common Stock	02/12/2019	S ⁽¹⁾	42,500	D	\$ 17.06	670,856	D

(4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock Option (right to buy)	\$ 2.62	02/08/2019		M	11,667	10/01/2012 ⁽⁵⁾ 09/28/2022	Common Stock 11,667
Stock Option (right to buy)	\$ 2.62	02/11/2019		M	11,667	10/01/2012 ⁽⁵⁾ 09/28/2022	Common Stock 11,667
Stock Option (right to buy)	\$ 2.01	02/12/2019		M	42,500	06/01/2013 ⁽⁵⁾ 05/06/2023	Common Stock 42,500

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other

GIVEN BRUCE D
225 S. LAKE AVENUE
SUITE 1050
PASADENA, CA 91101

Chief Operating Officer

Signatures

/s/ Bruce Given

02/12/2019

 Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$14.48 to \$15.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- (2) The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.23 to \$16.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- (3) The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$17.03 to \$17.21, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- (4) Represents first vesting date. Option vested over four years from date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.